AU2016230827B2 - Methods of reducing serum levels of fc-containing agents using fcrn antagonists - Google Patents

Methods of reducing serum levels of fc-containing agents using fcrn antagonists Download PDF

Info

Publication number
AU2016230827B2
AU2016230827B2 AU2016230827A AU2016230827A AU2016230827B2 AU 2016230827 B2 AU2016230827 B2 AU 2016230827B2 AU 2016230827 A AU2016230827 A AU 2016230827A AU 2016230827 A AU2016230827 A AU 2016230827A AU 2016230827 B2 AU2016230827 B2 AU 2016230827B2
Authority
AU
Australia
Prior art keywords
fcrn
antagonist
region
subject
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016230827A
Other languages
English (en)
Other versions
AU2016230827A1 (en
Inventor
Christophe Blanchetot
Johannes De Haard
Torsten Dreier
Nicolas G.H. Ongenae
Peter Ulrichts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2016230827A1 publication Critical patent/AU2016230827A1/en
Application granted granted Critical
Publication of AU2016230827B2 publication Critical patent/AU2016230827B2/en
Priority to AU2021277720A priority Critical patent/AU2021277720B2/en
Assigned to argenx BV reassignment argenx BV Request to Amend Deed and Register Assignors: ARGENX BVBA
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016230827A 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonists Active AU2016230827B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021277720A AU2021277720B2 (en) 2015-03-09 2021-12-02 Methods of reducing serum levels of Fc-containing agents using FcRn antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130076P 2015-03-09 2015-03-09
US62/130,076 2015-03-09
PCT/IB2016/000398 WO2016142782A1 (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021277720A Division AU2021277720B2 (en) 2015-03-09 2021-12-02 Methods of reducing serum levels of Fc-containing agents using FcRn antagonists

Publications (2)

Publication Number Publication Date
AU2016230827A1 AU2016230827A1 (en) 2017-08-24
AU2016230827B2 true AU2016230827B2 (en) 2021-10-28

Family

ID=55863122

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016230827A Active AU2016230827B2 (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonists
AU2021277720A Active AU2021277720B2 (en) 2015-03-09 2021-12-02 Methods of reducing serum levels of Fc-containing agents using FcRn antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021277720A Active AU2021277720B2 (en) 2015-03-09 2021-12-02 Methods of reducing serum levels of Fc-containing agents using FcRn antagonists

Country Status (19)

Country Link
US (1) US20160264669A1 (cg-RX-API-DMAC7.html)
EP (2) EP4006051A1 (cg-RX-API-DMAC7.html)
JP (5) JP2018509413A (cg-RX-API-DMAC7.html)
KR (1) KR102720769B1 (cg-RX-API-DMAC7.html)
AU (2) AU2016230827B2 (cg-RX-API-DMAC7.html)
CA (1) CA2978253A1 (cg-RX-API-DMAC7.html)
DK (1) DK3268391T3 (cg-RX-API-DMAC7.html)
EA (1) EA038178B1 (cg-RX-API-DMAC7.html)
ES (1) ES2882999T3 (cg-RX-API-DMAC7.html)
HU (1) HUE056775T2 (cg-RX-API-DMAC7.html)
IL (2) IL254403B (cg-RX-API-DMAC7.html)
LT (1) LT3268391T (cg-RX-API-DMAC7.html)
MX (2) MX386491B (cg-RX-API-DMAC7.html)
MY (1) MY188761A (cg-RX-API-DMAC7.html)
PL (1) PL3268391T3 (cg-RX-API-DMAC7.html)
PT (1) PT3268391T (cg-RX-API-DMAC7.html)
SG (2) SG10201908259WA (cg-RX-API-DMAC7.html)
WO (1) WO2016142782A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109042B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3087095T3 (da) 2013-12-24 2019-10-28 Argenx Bvba FcRn-antagonist og fremgangsmåder til anvendelse
SG11201705475QA (en) * 2015-01-30 2017-08-30 Momenta Pharmaceuticals Inc Fcrn antibodies and methods of use thereof
AU2016230827B2 (en) * 2015-03-09 2021-10-28 argenx BV Methods of reducing serum levels of fc-containing agents using fcrn antagonists
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
AU2018380979B2 (en) * 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
MX2020013195A (es) 2018-06-08 2021-02-26 Argenx Bvba Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.
US20220081481A1 (en) * 2019-01-16 2022-03-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2021014756A (es) * 2019-06-07 2022-01-18 Argenx Bvba Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea.
MX2022001038A (es) * 2019-07-25 2022-04-26 Genzyme Corp Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn.
CN115836086A (zh) 2020-01-08 2023-03-21 阿尔金克斯有限公司 治疗天疱疮病症的方法
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2021257668A1 (en) * 2020-06-17 2021-12-23 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
KR20240036076A (ko) * 2021-08-13 2024-03-19 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Fcrn을 특이적으로 인식하는 항체 및 이의 용도
AU2023290529A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn/antigen-binding molecules and methods of use
JP2025537777A (ja) * 2022-11-14 2025-11-20 アルジェニクス ビーブイ ＦｃＲｎアンタゴニスト分子及びそれらの使用方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2013063186A2 (en) * 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
WO2013074598A1 (en) * 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) * 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
WO2002040047A2 (en) 2000-11-20 2002-05-23 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
HUP0700103A3 (en) 2001-08-03 2012-09-28 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP4524181B2 (ja) 2002-05-30 2010-08-11 マクロジェニクス，インコーポレーテッド Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP2272533A1 (en) 2003-01-13 2011-01-12 MacroGenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
AU2008254951A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
TWI504409B (zh) * 2009-03-25 2015-10-21 Genentech Inc 新穎抗－α５β１抗體及其用途
CA2837184C (en) * 2011-05-25 2021-09-21 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
JP6285923B2 (ja) * 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
DK3087095T3 (da) * 2013-12-24 2019-10-28 Argenx Bvba FcRn-antagonist og fremgangsmåder til anvendelse
AU2016230827B2 (en) * 2015-03-09 2021-10-28 argenx BV Methods of reducing serum levels of fc-containing agents using fcrn antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2013063186A2 (en) * 2011-10-26 2013-05-02 Novartis Animal Health Us, Inc. Monoclonal antibodies and methods of use
WO2013074598A1 (en) * 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Anonymous, "arGEN-X announces positive preclinical results for ARGX-113 Euronext", (2014-08-19), URL: https://www.euronext.com/nl/node/506652, (2016-08-01) *
Anonymous, (2014-04-24), URL: http://www.argen-x.com/en-GB/news-internal/argen-x-advances-argx-113-into-preclinical-development-for-autoimmune-disorders/60/, (2016-08-01) *
Argen-X, "arGEN-X N.V.", (2014-06-20), URL: https://www.afm.nl/registers/emissies_documents/14414.pdf, (2016-08-01) *
CARLOS VACCARO ET AL, "Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels", NATURE BIOTECHNOLOGY, (2005-10-01), vol. 23, no. 10, doi:10.1038/nbt1143, ISSN 1087-0156, pages 1283 - 1288 *
D. A. PATEL ET AL, "Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model", THE JOURNAL OF IMMUNOLOGY, US, (2011-07-15), vol. 187, no. 2, doi:10.4049/jimmunol.1003780, ISSN 0022-1767, pages 1015 - 1022 *
DILIP K. CHALLA ET AL, "Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis", MABS, US, (2013-09-01), vol. 5, no. 5, doi:10.4161/mabs.25439, ISSN 1942-0862, pages 655 - 659 *
Quinlin Hanson, "The role of the Immunoglobulin G1 Fc N-glycan in Fc[gamma]RIIIa affinity", ISBN 978-1-321-59176-7, (2014-01-01), URL: http://lib.dr.iastate.edu/cgi/viewcontent.cgi?article=5142&context=etd, (2016-08-03) *
Sandra Grau ET AL, (2011-09-21), URL: http://www.cisbio.com/sites/default/files/ressources/cisbio-pr-igg-core-a-fucosylation-and-its-impact-on-fc-gamma-riiia-binding.pdf, (2016-08-01) *
YUTAKA KANDA ET AL, GLYCOBIOLOGY, vol. 17, no. 1, (2007), pages 104 - 118 *

Also Published As

Publication number Publication date
JP7391132B2 (ja) 2023-12-04
JP2018509413A (ja) 2018-04-05
LT3268391T (lt) 2021-09-10
NZ734416A (en) 2024-12-20
EA038178B1 (ru) 2021-07-20
JP2022084868A (ja) 2022-06-07
JP7050191B2 (ja) 2022-04-07
AU2016230827A1 (en) 2017-08-24
SG11201707053SA (en) 2017-09-28
JP7403575B2 (ja) 2023-12-22
ES2882999T3 (es) 2021-12-03
MX386491B (es) 2025-03-18
SG10201908259WA (en) 2019-10-30
EP3268391B1 (en) 2021-08-11
PT3268391T (pt) 2021-08-19
WO2016142782A1 (en) 2016-09-15
MY188761A (en) 2021-12-29
KR20170131463A (ko) 2017-11-29
EA201791984A1 (ru) 2017-12-29
MX2021011633A (es) 2021-10-22
IL295425A (en) 2022-10-01
BR112017019191A2 (pt) 2018-05-02
IL254403A0 (en) 2017-11-30
JP2022105084A (ja) 2022-07-12
PL3268391T3 (pl) 2022-01-03
CA2978253A1 (en) 2016-09-15
JP2021073282A (ja) 2021-05-13
JP2024037846A (ja) 2024-03-19
HUE056775T2 (hu) 2022-03-28
EP3268391A1 (en) 2018-01-17
AU2021277720A1 (en) 2021-12-23
MX2017011534A (es) 2018-04-10
US20160264669A1 (en) 2016-09-15
IL254403B (en) 2022-09-01
ZA202109042B (en) 2025-01-29
DK3268391T3 (da) 2021-09-13
KR102720769B1 (ko) 2024-10-22
AU2021277720B2 (en) 2025-03-27
EP4006051A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
AU2021277720B2 (en) Methods of reducing serum levels of Fc-containing agents using FcRn antagonists
US20220275035A1 (en) Fcrn antagonists and methods of use
HK40066057A (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
HK40034924B (zh) Fcrn拮抗剂及使用方法
HK40034924A (en) Fcrn antagonists and methods of use
HK1242347B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
HK1242347A1 (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
BR112017019191B1 (pt) Métodos para reduzir níveis de soro de agentes que contêm fc utilizando antagonistas de fcrn

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS OF REDUCING SERUM LEVELS OF FC-CONTAINING AGENTS USING FCRN ANTAGONISTS

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: ARGENX BV

Free format text: FORMER NAME(S): ARGENX BVBA